Changping Wu
Overview
Explore the profile of Changping Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
5298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang C, Chen L, Xie X, Wu C, Wang Q
Comput Assist Surg (Abingdon)
. 2025 Jan;
30(1):2456303.
PMID: 39840821
Desmoid fibromatosis (DF) is a rare low-grade benign myofibroblastic neoplasm that originates from fascia and muscle striae. For giant chest wall DF, surgical resection offer a radical form of treatment...
2.
Xu X, Liu J, Fang C, Deng X, Zhu D, Jiang J, et al.
Cancer Biol Ther
. 2024 Nov;
25(1):2432690.
PMID: 39575888
To explore role of NAALADL2-AS2 as ceRNA in DLBCL. Fluorescence in situ hybridization was used to determine location of NAALADL2-AS2 in cells and to verify its expression in DLBCL tissues....
3.
Li W, You J, Xue H, Liu Y, Chen J, Zheng X, et al.
Cancer Immunol Immunother
. 2024 Aug;
73(10):207.
PMID: 39105870
Background: HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable...
4.
Shi X, Wu C, Deng W, Wu J
Medicine (Baltimore)
. 2024 Jul;
103(30):e39097.
PMID: 39058821
With the continuous improvement of treatment strategy, the prognostic value of international prognostic index (IPI) alone is limited for diffuse large B-cell lymphoma (DLBCL). Our study aims to explore the...
5.
Geng Y, Zheng X, Zhang D, Wei S, Feng J, Wang W, et al.
Biol Direct
. 2024 May;
19(1):36.
PMID: 38715141
Epidermal growth factor receptor (EGFR)-targeted therapy is an important treatment for RAS wild-type metastatic colorectal cancer (mCRC), but the resistance mechanism remains unclear. Here, the differential expression of circRNAs between...
6.
He Y, Chen Y, Li Z, Wu C
J Cancer Res Clin Oncol
. 2024 Jan;
150(2):30.
PMID: 38270643
Background And Aim: As the first identified mA demethylase, FTO has been implicated in the progression of various cancers. However, the specific mechanism of FTO in clear cell renal cell...
7.
Cheng G, Wu J, Ji M, Hu W, Wu C, Jiang J
BMC Cancer
. 2023 Sep;
23(1):825.
PMID: 37667220
Background: Effective identification and development of new molecular methods for the diagnosis, treatment and prognosis of lung adenocarcinoma (LUAD) remains an urgent clinical need. DNA methylation patterns at cytosine bases...
8.
Chen L, Huang H, Huang Z, Chen J, Liu Y, Wu Y, et al.
World J Surg Oncol
. 2023 Apr;
21(1):124.
PMID: 37024870
Background: Tissue-resident CD8T cells (CD103CD8T cells) are the essential effector cell population of anti-tumor immune response in tissue regional immunity. And we have reported that IL-33 can promote the proliferation...
9.
Cen S, Cai M, Wang Y, Lu X, Chen Z, Chen H, et al.
Front Genet
. 2022 Oct;
13:991875.
PMID: 36246583
We have already demonstrated that mesenchymal stem cells from patients with ankylosing spondylitis (ASMSCs) exhibited greater adipogenic differentiation potential than those from healthy donors (HDMSCs). Here, we further investigated the...
10.
Zheng X, Wang Q, Zhou Y, Zhang D, Geng Y, Hu W, et al.
Cancer Commun (Lond)
. 2022 Oct;
42(12):1347-1366.
PMID: 36209353
Background: N-acetyltransferase 10 (NAT10) is the only enzyme known to mediate the N4-acetylcytidine (ac4C) modification of mRNA and is crucial for mRNA stability and translation efficiency. However, its role in...